IACH News

Give the high rate of advances in the field of clinical hematology, the IACH News initiative enables experts in the field and key opinion leaders share the most up to date information in a timely manner, and in a format that is, focused, engaging and easy to access.

Sort By Categories

Dr. Oluwole Olalekan- Approval of Polatuzumab Vedotin Plus R-CHP in Previously Untreated DLBCL

Dr. Bhagirathbhai Dholaria- Omisirge Allogeneic Cord Blood-Based Cell Therapy Approved to Reduce Risk of Infection Following Stem Cell Transplantation

Dr. Paula Rodríguez Otero- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Prof. Christoph Stein Thoeringer- Role of the Gut Microbiome in CAR-T cell Therapy

Dr. Doris Hansen- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium

Prof. Florent Malard- The First microbiota therapy approved by the US FDA

Prof. Marion Subklewe- T-cell exhaustion induced by continuous bispecific molecule exposure

Prof. Mohamad Mohty – FDA Breakthrough Therapy Designation for Elranatamab in Relapsed or Refractory Multiple Myeloma

Dr. Eolia Brissot – Positive opinion of the CHMP on tabelecleucel for the treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

Prof. Mohamed Kharfan Dabaja – Positive Results from Final Progression-Free Survival Analysis of zanubrutinib Compared to ibrutinib in CLL

Dr. Areej El-Jawahri – Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma

Prof. He Huang – Non-viral, specifically targeted CAR-T cells, achieve high safety and efficacy in B-NHL

Prof. Mikkael Sekeres – Azacitidine plus venetoclax for myelodysplastic syndromes

Dr. Adi Nagler – Single cell sequencing to chronic lymphocytic leukemia

Prof. Meral Beksac – The recent developments in the field of bispecific T-cell engagers

Prof. Selim Corbacioglu – The importance of veno-occlusive disease prophylaxis

Prof. Paul Richardson – Melflufen for the treatement of relapsed-refractory myeloma

Prof. Mohamad Mohty – New treatments for refractrory acute GVHD

Dr. Eolia Brissot – Approval of maribvir for post-transplant cytomegalovirus infection

Prof. Sebastian Giebel – CAR T cells for adult ALL

Prof. Farhad Ravandi – MRD in AML

Prof. Iskra Pusic – Recent updated in Acute GVHD

Prof. Arnon Kater -State of the art therapy in CLL

Annalisa Ruggeri – Haplo versus matched unrelated transplant at the era of post-cyclophosphamide

Christopher Hourigan – How to distinguish to Acute Myeloid Leukemia from Non-Malignant Clonal Hematopoiesis?

Robert Zeiser – REACH3 trial results

Alex Lazaryan – Belumosudil’s FDA approval for cGVHD

Monzr Al Malki – The role of post cyclophosphamide, for GVHD prophylaxis, in the mismatched unrelated setting

Naveen Pemmaraju – Novel Therapeutic Approaches in BPDCN

Jurgen Kuball – Gammadelta T cells

Anna Sureda – Therapy of lymphomas, what’s new at EHA 2021

Nitin Jain – Therapy of CLL, what’s new at EHA 2021

Gram Jackson – Recently released paper on Improving prognostic assignment in older adults with MM

Mehdi Hamadani – Recently released ZUMA-7 trial results

Saad Usmani – Take-home messages, from ASCO, and EHA 2021

Luciano J. Costa – The role of auto in myeloma based on the ASCO 21 data

Jesus G. Berdeja – Results of the CARTITUDE-1 study

Arnon Nagler – Allo-transplant for AML: what’s new at EHA 2021

Mohamad Mohty – Advances in Multiple Myeloma as reported at EHA 2021

Ruben Mesa – Therapy of MPNs: what’s new at EHA 2021?

Dr. Jordan Gauthier – Results from Phase 3 TRANSFORM Trial

Dr. Jim Omel – The patient / cancer research advocate viewpoint from ASCO 2021

Prof. Mohamad Mohty – Multiple myeloma take home messages from ASCO 2021

Go to Top